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Interleukin-33 (IL-33) is a member of the IL-1 family and
is involved in polarization of T cells toward a T helper 2
(Th2) cell phenotype. IL-33 is thought to be activated
via caspase-1-dependent proteolysis, similar to the
proinflammatory cytokines IL-1b and IL-18, but this
remains unproven. Here we showed that IL-33 was
processed by caspases activated during apoptosis
(caspase-3 and -7) but was not a physiological
substrate for caspases associated with inflammation
(caspase-1, -4, and -5). Furthermore, caspase-depen-
dent processing of IL-33 was not required for ST2
receptor binding or ST2-dependent activation of the
NF-kB transcription factor. Indeed, caspase-depen-
dent proteolysis of IL-33 dramatically attenuated IL-
33 bioactivity in vitro and in vivo. These data suggest
that IL-33 does not require proteolysis for activation,
but rather, that IL-33 bioactivity is diminished through
caspase-dependent proteolysis within apoptotic cells.
Thus, caspase-mediated proteolysis acts as a switch
to dampen the proinflammatory properties of IL-33.
INTRODUCTION
Caspasesare highly specificproteases that havebeen implicated
in apoptosis and inflammation (Creagh et al., 2003; Martinon and
Tschopp, 2004). Caspase-1, -4, and -5 are activated in response
to pathogen products, such as lipopolysaccharide (LPS), that
signal via members of the Toll-like receptor (TLR) and Nod-like
receptor families (MartinonandTschopp, 2004).Caspase-1plays
a critical role in the innate immune response to infectious agents
through proteolytic processing of pro-interleukin-1b (pro-IL-1b)
and pro-IL-18 to their mature forms (reviewed in Creagh et al.
[2003]).
Recently, caspase-1 has also been implicated in the proteo-
lytic maturation of the IL-1 family cytokine, IL-33 (also known84 Immunity 31, 84–98, July 17, 2009 ª2009 Elsevier Inc.as IL-1F11) (Schmitz et al., 2005). IL-33 is a ligand for the IL-1R
family member ST2 (T1), which has previously been linked with
maturation of T helper 2 (Th2) cells and negative regulation of
IL-1R and TLR4 signaling (Xu et al., 1998; Meisel et al., 2001;
Brint et al., 2004). Antagonistic antibodies against ST2 or IgG-
ST2 fusion proteins lead to enhancement of Th1 cell responses
and attenuation of Th2 cell-associated effects (Lohning et al.,
1998; Xu et al., 1998).
Relatively little is known concerning the factors that stimulate
IL-33 production and secretion. An artificially truncated form of
this cytokine enhances production of Th2 cell cytokines from
in vitro-polarized Th2 cells and suppresses Th1 cell cytokine
production (Schmitz et al., 2005). Administration of the same trun-
cated form of IL-33 in vivo induces expression of IL-4, IL-5, and
IL-13andalso leads toeosinophilia, splenomegaly, and increased
amounts of serum immunoglobulin E (IgE) and IgA (Schmitz et al.,
2005; Chackerian et al., 2007). IL-33 is also a potent activator of
eosinophils, basophils, and mast cells and can promote in vitro
maturation of the latter frombonemarrowprecursors (Allakhverdi
et al., 2007; Ali et al., 2007; Pecaric-Petkovic et al., 2009).
The role of caspase-1, or other inflammatory caspases, in the
maturation of IL-33 remains enigmatic. High concentrations of
caspase-1 are reported to cleave IL-33 in vitro, and this is
proposed as a mechanism of activation of this cytokine, similar
to IL-1b (Schmitz et al., 2005). However, the functional conse-
quences of caspase-mediated proteolysis of IL-33 are not
known because the activity of the full-length cytokine has not
been investigated. Nor is it known whether IL-33 is cleaved by
caspase-1 at physiological concentrations.
Here, we have examined the role of caspase-1, -4, and -5 in
the maturation of IL-33. Surprisingly, we found little evidence
that IL-33 is a physiological substrate for the inflammatory cas-
pases. Rather, we showed that this cytokine was efficiently pro-
cessed by caspases-3 and -7, proteases that are selectively
activated during apoptosis. Furthermore, caspase-mediated
proteolysis of IL-33 dramatically attenuated IL-33 biological
activity in vitro and in vivo. Mutation of a single amino acid
located within the caspase cleavage site of IL-33 also eliminated
the biological activity of this cytokine, suggesting that this region
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Inactivation of IL-33 by Apoptotic CaspasesFigure 1. Processing of IL-33 by Apoptotic but Not Inflammatory Caspases
(A) 35S-labeled hIL-33, mIL-33, and IL-1b were prepared by in vitro transcription and translation and were then incubated with the indicated concentrations of
recombinant caspase-1, -4, and -5 for 2 hr at 37C followed by analysis by SDS-PAGE and fluorography.
(B) Recombinant caspase-1, -3, and -7 were added to Jurkat cell-free extracts, at the indicated concentrations, followed by incubation at 37C for 2 hr. Extracts
were then analyzed by SDS-PAGE followed by immunoblotting for the indicated substrate proteins.
(C) 35S-labeled hIL-33, mIL-33, and IL-1b, prepared by in vitro transcription and translation, were incubated with the indicated concentrations of recombinant
caspase-1, -3, and -7 for 2 hr at 37C followed by analysis by SDS-PAGE and fluorography.
(D) Densitometric analysis of the gels presented in (C). Scanned gels were analyzed with ImageJ software, and results are expressed as % proteolysis of the
full-length forms of each protein relative to the untreated control.
Panels (A)–(D) represent data from at least three independent experiments.is critical for IL-33 activity. Thus, IL-33 is preferentially processed
by caspases activated during apoptosis rather than inflamma-
tion and this serves to reduce, rather than enhance, IL-33 activity
in vivo.
RESULTS
IL-33 Is a Poor Substrate for Caspase-1
Toexplorewhether IL-33 is aphysiological substrate for caspases
activated during inflammation, we incubated in vitro-transcribed
and -translated human andmouse IL-33 in the presence of phys-
iologically relevant amounts of caspase-1, -4, and -5 (Figure 1A).
We used nonsaturating concentrations of caspase-1 that
achieved robust proteolysis of the known caspase-1 substrate,
IL-1b, and equimolar amounts of caspase-4 and -5. All caspases
were active as indicated by hydrolysis of the synthetic peptide
substrate WEHD-AMC (Figure S1 available online). However,although caspase-1 robustly cleaved IL-1b, IL-33 was not readily
processed under the sameconditions (Figure 1A).Caspase-4 and
-5also failed toprocess IL-33, suggesting that, in comparisonwith
IL-1b, IL-33 is a poor substrate for the inflammatory caspases.
IL-33 Is a Substrate for Caspases Activated
during Apoptosis
We next explored whether IL-33 could be cleaved by caspases
that are activated during apoptosis rather than inflammation.
Caspase-3 and -7 act as the major effector caspases within
the cell-death machinery (Walsh et al., 2008); therefore, we
used concentrations of caspase-3 and -7 that achieved robust,
but incomplete, proteolysis of their known substrates, Rho
GDP dissociation inhibitor (RhoGDI), cochaperone p23, and
X-linked inhibitor of apoptosis protein (XIAP) (Figure 1B). These
concentrations were chosen to avoid the use of saturating,
nonphysiological amounts of the latter proteases.Immunity 31, 84–98, July 17, 2009 ª2009 Elsevier Inc. 85
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Inactivation of IL-33 by Apoptotic CaspasesFigure 2. Proteolysis of IL-33 at Asp178 Occurs under Conditions of Apoptotic but Not Inflammatory Caspase Activation
(A) Cell-free extracts derived from THP-1 cells were incubated at 37C to permit spontaneous activation of inflammatory caspases (Inflammasome) or in the pres-
ence of 50 mg/ml cytochrome c and 1 mM dATP to promote activation of apoptotic caspases (Apoptosome). As a control, caspase activation was suppressed
through addition of 5 mMYVAD-CHO. Extracts were then immunoblotted for caspase-1, caspase-3, and IL-1b, as indicated. Representative blots are shown from
at least three independent experiments.86 Immunity 31, 84–98, July 17, 2009 ª2009 Elsevier Inc.
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Inactivation of IL-33 by Apoptotic CaspasesAs Figures 1C and 1D illustrate, caspase-3 and -7 readily
processed human and murine IL-33, with caspase-7 being
more efficient in this regard. Importantly, caspase-3 and -7
failed to cleave IL-1b under the same conditions (Figure 1C).
Whereas robust IL-33 processing was observed at low concen-
trations (3–7 nM) of caspase-7, caspase-1 failed to cleave IL-33
even at several-fold-higher concentrations. Once again, cas-
pase-1 readily processed IL-1b under conditions where it
failed to process IL-33 to any substantial degree (Figures 1A
and 1C). These data argue that IL-33 is preferentially cleaved
by caspases that are activated during apoptosis as opposed
to inflammation.
Proteolysis of IL-33 in Apoptotic Cell-Free Extracts
To explore IL-33 processing further, we used a cell-free system
based upon cytosolic extracts derived from LPS-treated mono-
cytic THP-1 cells, where caspase-1, -4, and -5 can be activated
by incubating these extracts at 37C (Yamin et al., 1996; Marti-
non et al., 2002). Upon incubation of THP-1 cell-free extracts
at 37C, caspase-1 was processed to its active form and matu-
ration of endogenous IL-1b was readily detected (Figure 2A). As
expected, caspase-3 was not activated under these conditions,
as indicated by the failure of this protease to undergo proteolytic
processing (Figure 2A). In sharp contrast to the robust process-
ing of IL-1b seen under these conditions, processing of human or
mouse IL-33was barely detectable (Figure 2B), again suggesting
that IL-33 is a poor substrate for caspase-1 and other caspases
activated under inflammatory conditions.
With the same THP-1 cell-free system, caspase-3 and -7 can
be activated by addition of cytochrome c and deoxyadenosine
triphosphate (dATP) to the extracts, because the latter act as
cofactors for assembly of the Apaf-1-caspase-9 apoptosome,
which activates these caspases downstream (reviewed in
Creagh et al., 2003). Under these conditions, caspase-1 activa-
tion was attenuated and IL-1b proteolysis was much less effi-
cient, whereas caspase-3 was robustly activated (Figure 2A).
In contrast to the lack of processing of IL-33 under conditions
where caspase-1 was clearly activated, IL-33 was processed
very efficiently upon activation of caspase-3 and -7 through
addition of cytochrome c and dATP (Figure 2B), again arguing
that IL-33 is preferentially cleaved by caspases activated during
apoptosis but not inflammation.
We also used a cell-free system based upon cytosolic extracts
of Jurkat cells, which are essentially devoid of caspase-1 (Chowet al., 1999). Addition of cytochrome c and dATP to Jurkat
extracts resulted in rapid activation of caspase-3 and -7 and
proteolytic processing of known caspase substrates, such as
XIAP and cochaperone p23 (Figure S2A). Proteolysis of human
and murine IL-33 was again readily observed under these condi-
tions (Figure S2B). Taken together with our earlier observations
made with recombinant caspases (Figure 1), these results
strongly suggest that IL-33 is a physiological substrate for cas-
pases activated during apoptosis but is cleaved very inefficiently
at physiologically relevant concentrations of caspase-1.
IL-33 Is Cleaved at a Single Conserved Site
It has been proposed that human IL-33 is cleaved by caspase-1
at Asp110 and that this represents the biologically active form of
this cytokine (Schmitz et al., 2005). However, this site is not
conserved between the human and murine forms of IL-33,
making it highly unlikely that IL-33 is processed at this residue
(Figure 2C). To identify the caspase-processing site within
IL-33, we inspected the human and mouse IL-33 sequences
for conserved tetrapeptide motifs containing Aspartate (Asp)
residues that may qualify as caspase cleavage motifs. On the
basis of the approximate molecular weights of the caspase-
mediated cleavage products of IL-33 observed in our initial
experiments (Figures 1C and 2B), a conserved caspase cleavage
motif that was more likely to represent the site of caspase-medi-
ated proteolysis was located at Asp178 within human IL-33
(175DGVD178) and Asp175 within murine IL-33 (172DGVD175)
(Figure 2C). Notably, this site also conforms to a consensus cas-
pase-3 and -7 DXXD cleavage motif, rather than the WI/V/LXD
motif preferred by caspase-1.
We therefore expressed truncations of human IL-33 corre-
sponding to the putative cleavage products generated through
processing at Asp178. As can be seen from Figure 2D, these
truncated IL-33 proteins displayed precisely the same SDS-
PAGE mobilities as the caspase-7-cleaved form of IL-33.
Furthermore, the truncated IL-33 mutants failed to be further
processed by caspase-7 (Figure 2D), strongly suggesting that
human IL-33 is processed at Asp178 and not Asp110, as
previously claimed. We also expressed recombinant full-length
GST-IL-33 in bacteria and cleaved this protein with caspase-7
(Figure 2E). The resulting fragments were then analyzed with
MALDI-TOF mass spectrometry, and the peptide coverage of
these fragments strongly indicated that the caspase cleavage
site was located between amino acids 159 and 187 (Figure S3),(B) 35S-labeled hIL-33, mIL-33, and IL-1b were added to THP-1 cell-free extracts followed by treatment as described in (A). Reactions were sampled at the
indicated times and were subsequently analyzed by SDS-PAGE and fluorography. Representative gels are shown from at least two independent experiments.
(C) Schematic representation of human andmurine IL-33 depicting potential caspase cleavagemotifs. Note that the proposed site of caspase-1-mediated prote-
olysis (ALHD110; Schmitz et al., 2005) is not conserved between human and mouse IL-33.
(D) 35S-labeled full-length (FL) hIL-33 and the indicated IL-33 deletion mutants were incubated in the presence of recombinant caspase-7 (40 nM) for 2 hr at 37C
followed by analysis by SDS-PAGE and fluorography. Representative gels are shown from at least two independent experiments.
(E) Recombinant GST-IL-33 was incubated for 2 hr at 37C in the presence or absence of recombinant caspase-7 (600 nM), as indicated, followed by SDS-PAGE
and Coomassie blue staining. Representative gels are shown from at least two independent experiments.
(F) 35S-labeled wild-type hIL-33 and IL-33D178A point mutant were incubated for 2 hr at 37C with recombinant caspase-3, -7, and -1, as shown. Reactions were
analyzed by SDS-PAGE and fluorography. Representative gels are shown from at least two independent experiments.
(G) 35S-labeled wild-type hIL-33 and IL-33D178A point mutant were added to Jurkat cell-free extracts followed by activation of apoptotic caspases by addition of
cytochrome c and dATP. Reactions were sampled at the indicated times and were subsequently analyzed by SDS-PAGE and fluorography. Samples of the same
reactions were also immunoblotted for caspase-3 and XIAP, as indicated. Representative gels and blots are shown from at least two independent experiments.
(H) Recombinant IL-33112-270 and IL-33112-270 D178A point mutant were incubated with recombinant caspase-7 (600 nM) for 4 hr at 37C followed by analysis by
SDS-PAGE and Coomassie blue staining. Representative gels are shown from at least three independent experiments.Immunity 31, 84–98, July 17, 2009 ª2009 Elsevier Inc. 87
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Inactivation of IL-33 by Apoptotic Caspaseswhich encompassed the conserved DGVD175/178 motif dis-
cussed above. We then generated point mutations in human
and murine IL-33 corresponding to the putative caspase
cleavage site (Asp178 in human and Asp175 in mouse), and
these mutants were completely resistant to processing by
any of the caspases examined (Figure 2F and data not shown).
Furthermore, this point mutant was also completely protected
from proteolysis in apoptotic Jurkat cell-free extracts under
conditions where wild-type IL-33 was completely cleaved
(Figure 2G).
On the basis of the initial observations by Schmitz et al. (2005),
all investigations carried out to date with IL-33 have used an
artificially truncated form of this cytokine, IL-33112-270, that is
proposed to represent the caspase-cleaved form of this protein.
However, our experiments indicate that this form of IL-33 would
still contain the actual caspase cleavage site and therefore be
susceptible to caspase-mediated proteolysis. To confirm this,
we also generated the artificially truncated form of IL-33 (amino
acids 112–270) as well as the D178A mutant form of this trunca-
tion. As Figure 2H shows, IL-33112-270 was cleaved by caspase-
7, whereas the IL-33112-270 D178A mutant was completely resis-
tant to proteolysis.
These data demonstrate that IL-33 is cleaved by caspase-3
and -7 within a conserved motif at Asp178 in the human form
of this cytokine (Asp175 in the mouse). This has important impli-
cations, given that all previous studies on IL-33 have exclusively
used a truncated form of this protein based on a predicted
caspase cleavage site (at Asp110) that has failed to be verified
by our investigations and is not conserved between human
and mouse IL-33.
IL-33 Is Cleaved during Apoptosis
To confirm that IL-33 is cleaved during apoptosis in a cellular
context, we transiently overexpressed FLAG-tagged IL-33 in
human HeLa cells and induced these cells to die by exposure
to a panel of proapoptotic stimuli, including Daunorubicin, tumor
necrosis factor (TNF), and Cisplatin (Figure 3A). Robust process-
ing of IL-33 was observed under conditions where apoptosis
was initiated, but importantly, the IL-33D178A point mutant was
not cleaved under the same conditions (Figure 3B). Furthermore,
inhibition of caspase activation or activity in HeLa cells, through
overexpression of Bcl-xL or by inclusion of a polycaspase inhib-itor (z-VAD-fmk) in the medium, also blocked apoptosis-associ-
ated proteolysis of IL-33 (Figures 3C and 3D). Thus, IL-33 is
cleaved during apoptosis, and this occurs at the same site
(Asp178) of caspase-mediated processing of IL-33 in vitro.
We also asked whether murine embryonic fibroblasts (MEFs)
lacking Casp1, Casp3, or Casp7 processed IL-33 during
apoptosis. As Figure 3E shows, whereas IL-33 was readily
processed upon induction of apoptosis in wild-type MEFs,
Casp1/MEFs still retained the ability to process this cytokine,
underscoring our earlier observations that caspase-1 is unlikely
to cleave IL-33. In sharp contrast, processing of IL-33 was
completely attenuated inCasp3/MEFs under the same condi-
tions (Figure 3E). Casp7/ MEFs exhibited processing of IL-33
similar to wild-type cells (Figure 3E), most likely because cas-
pase-3 and -7 exhibit functional redundancy with respect to
many caspase substrates, although this is unidirectional in
many contexts because caspase-3 is a more abundant enzyme
in certain cell types (Walsh et al., 2008).
Endogenous IL-33 is Preferentially Released
during Necrosis
To ask whether endogenous IL-33 behaved similarly to the over-
expressed cytokine, we initially explored conditions for induction
of IL-33 protein expression in THP-1 cells, because previous
studies have not addressed this issue. As shown in Figures 4A
and 4B, THP-1 cells did not express IL-33 constitutively but
were induced to do so upon stimulation with LPS and PMA,
similar to IL-1b. However, in contrast to IL-1b, IL-33 remained
completely cell associated and was not detected in medium
from LPS- and PMA-stimulated cells (Figure 4C). Furthermore,
the form of IL-33 that was detected under these conditions
was the full-length form of this cytokine (Figure 4B).
We also immunoprecipitated endogenous IL-33 from LPS-
and PMA-treated THP-1 cells to explore whether any of this
cytokine could be found in a cleaved form, but failed to detect
any cleaved IL-33 under these conditions (Figure 4D). However,
upon induction of apoptosis in THP-1 cells via cytotoxic drugs,
endogenous IL-33 was processed to a species that ran at an
identical mobility to the caspase-3- and caspase-7-cleaved
form of IL-33 (Figure 4E). Similar results were also obtained
when apoptosis was induced by the physiological death-
receptor ligands TNF, anti-Fas, or TRAIL (Figure S4). We alsoFigure 3. IL-33 Is Cleaved during Apoptosis
(A) HeLa cells were transfectedwith expression plasmids encoding either wild-type IL-33 (top panel) or IL-33D178A point mutant (bottom panel). Twenty-four hours
later, cells were then treated with Daunorubicin (Dauno; 5 mM), TNF (10 ng/ml), cycloheximide (CHX; 1 mM), and cisplatin (50 mM) and incubated for a further 8 hr
before assessment of apoptosis. Results are representative of at least three independent experiments. Error bars represent the mean ± the standard error of
the mean (SEM).
(B) Immunoblot analysis of IL-33, caspase-3, cochaperone p23, XIAP, and actin in cell lysates derived from HeLa cells transfected with either wild-type IL-33 (left
panel) or the D178A point mutant (right panel), followed by incubation in the presence or absence of Daunorubicin (Dauno), TNF and cycloheximide, or Cisplatin at
concentrations indicated in (A). Results are representative of at least three independent experiments.
(C) HeLa cells were transfected with an IL-33 expression plasmid for 24 hr followed by treatment for 8 hr with Daunorubicin (5 mM) to induce apoptosis. In parallel,
HeLa cells were also treated with the polycaspase inhibitor Z-VAD-fmk (50 mM) or were transfected with a Bcl-xL expression plasmid as indicated. Results are
representative of at least three independent experiments. Error bars represent the mean ± the SEM.
(D) Cell lysates were generated from the cells treated in (C) and were immunoblotted for the indicated proteins. Results are representative of at least three inde-
pendent experiments.
(E) Murine embryonic fibroblasts from wild-type (WT), Casp1/, Casp3/, or Casp7/ mice were transfected with an expression plasmid encoding hIL-33,
followed by treatment for 24 hr with MG132 (0.2-0.4 mM) to facilitate IL-33 stabilization. Cells then either were left untreated or were treated for 24–30 hr with
Staurosporine (40–80 mM) or Etoposide (0.5–1 mM) in order to achieve equivalent levels of cell death, followed by preparation of cell lysates and immunoblotting
for the indicated proteins. The % of apoptotic cells in each condition was assessed by direct cell counts on a minimum of 300 cells per treatment with standard
morphological criteria (bottom panel). Results are representative of at least three independent experiments. Error bars represent the mean ± the SEM.Immunity 31, 84–98, July 17, 2009 ª2009 Elsevier Inc. 89
Immunity
Inactivation of IL-33 by Apoptotic Caspases90 Immunity 31, 84–98, July 17, 2009 ª2009 Elsevier Inc.
Immunity
Inactivation of IL-33 by Apoptotic Caspasesasked whether IL-33 was secreted during apoptosis, but again
found that the majority of protein remained cell associated
(Figure 4F, left panels). In contrast, upon induction of necrosis
via hydrogen peroxide, sodium azide, streptolysin O, or a high
concentration of daunorubicin, IL-33 was now readily detected
in medium (Figure 4F, right panels).
We also performed similar experiments with primary bone
marrow-derived mouse dendritic cells. Similar to what was
observed in human THP-1 cells, IL-33 was upregulated upon
LPS and PMA treatment of murine DCs but was not proteo-
lytically processed or secreted under these conditions (Figures
S5A and S5B). IL-1bwas also induced upon LPS and PMA treat-
ment of DCs but, in contrast to IL-33, was secreted under these
conditions (Figure S5B). Upon triggering of apoptosis in these
cells, IL-33 was once again processed to a fragment consistent
with caspase-3- and caspase-7-dependent processing of this
cytokine (Figure S5C).
Collectively, the above data indicate that IL-33 is processed in
a caspase-dependent manner during apoptosis, but not in
response to a proinflammatory stimulus (LPS) associated with
caspase-1 activation. Furthermore, IL-33 appears to be prefer-
entially released during necrosis, with relatively minor amounts
being released from apoptotic cells.
IL-33 Does Not Require Proteolytic Processing
for Activity
Certain members of the IL-1 family, such as IL-1b, undergo
restricted proteolysis to convert their inactive precursors into
the active cytokine (Mosley et al., 1987). However, other cyto-
kines in this family, such IL-1a, displaybiological activity irrespec-
tive of whether they are proteolytically processed or not (Mosley
et al., 1987). Because all previous studies on IL-33 have used an
artificially truncated form of this cytokine (IL-33112-270) that does
not represent either the full-length or the bona fide caspase-
cleaved form of IL-33, it is therefore not clear how proteolysismodulates the activity of this cytokine, given that the biological
activity of full-length IL-33 has not been assessed.
To explore the impact of caspase-mediated proteolysis on the
biological activity of IL-33, we generated recombinant full-length
GST-IL-33 and incubated this protein with caspase-7 to
generate cleaved IL-33 protein (see Figure 2E). Note that
a GST-fusion protein was used due to the extreme insolubility
of full-length untagged IL-33 when expressed in bacterial or
yeast expression systems (data not shown). We then compared
the ability of full-length GST-IL-33, versus the caspase-cleaved
form of this protein, to promote NF-kB activation in an ST2-
receptor-dependent manner. For this purpose, we used
HEK293T cells transfected with the ST2 receptor along with
a NF-kB-responsive promoter. As Figure 5A illustrates, whereas
we detected NF-kB activation in response to the full-length IL-33
protein, the activity of the caspase-cleaved form of this protein
was dramatically attenuated. Similar results were also observed
with the artificially truncated form of IL-33 (amino acids 112–
270), which also exhibited reduced activity upon caspase-medi-
ated proteolysis (Figure 5A, bottom panel). These data suggest,
in direct opposition to the prevailing view, that caspase-medi-
ated proteolysis of IL-33 results in a decrease rather than an
increase in the activity of this cytokine. Moreover, our data also
suggest that full-length IL-33 is biologically active and does not
require proteolytic processing for acquisition of ST2-dependent
receptor activation.
We also compared the activity of full-length GST-IL-33 with
the artificially truncated version of this protein (amino acids
112–270; Figure 5B) that is currently used by most laboratories
as ‘‘mature’’ IL-33. As Figure 5C shows, IL-33112-270 had compa-
rable activity to full-length GST-IL-33 in the ST2-dependent
NF-kB reporter assay. However, as we have shown above, this
truncated form of IL-33 is not the form that would be produced
through caspase-dependent proteolysis. Therefore, we also
generated recombinant forms of IL-33 equivalent to theFigure 4. Endogenous IL-33 Is Upregulated in Response to LPS and Is Selectively Released during Necrosis
(A) THP-1 cells either were left untreated or were treated with LPS (5 mg/ml), PMA (50 nM), TNFa (50 ng/ml), IL-1a (50 ng/ml), IL-1b (50 ng/ml), IFNg (250 ng/ml), or
combinations of these agents, as indicated. Twenty-four hours later, lysates were generated and immunoblotted for IL-33.
(B) THP-1 cells were treated with PMA (50 nM) together with the indicated concentrations of LPS. Twenty-four hours later, lysates were generated and immuno-
blotted for the indicated proteins. As controls, in vitro-transcribed and -translated full-length IL-33, caspase-7-cleaved full-length IL-33, and artificially truncated
IL-33112-270 were included to facilitate size comparison.
(C) THP-1 cells were treated as in (B); then, 24 hr later, cells and medium were harvested separately and cells were lysed in cell lysis buffer (see Experimental
Procedures) to facilitate measurement of cell-associated cytokines. Cell-associated and -secreted IL-33 and IL-1b concentrations were then assessed by ELISA.
Results are representative of at least three independent experiments. Error bars represent the mean ± the SEM.
(D) Immunoprecipitation of endogenous IL-33. THP-1 cells (108) were treated with LPS (5 mg/ml) and PMA (50 nM) for 24 hr, followed by treatment with the pro-
teasome inhibitor MG132 (5 mM) for a further 24 hr to stabilize endogenous IL-33. Cells were lysed as in (C), then incubated overnight with Protein A/G agarose-
immobilized control or IL-33 antibody. Immune complexes were then immunoblotted for IL-33 as indicated. The arrow indicates full-length IL-33, whereas the
asterisk indicates antibody light chain used for the immunoprecipitation. As controls, in vitro-transcribed and -translated full-length IL-33 and caspase-7-cleaved
full-length IL-33 were included to facilitate size comparison. Results are representative of at least two independent experiments.
(E) THP-1 cells were treated with LPS (5 mg/ml) and PMA (50 nM); then, 24 hr later, MG132 (5 mM) was added to stabilize endogenous IL-33. After a further 6 hr,
cells were treated with the apoptosis-inducing agents Actinomycin D (Act D; 5 mM), Daunorubicin (Dauno; 10 mM), Cisplatin (500 mM), or MG132 (100 mM) and
incubated for a further 36 hr before assessment of apoptosis. The % of apoptotic cells (counts were performed on a minimum of 300 cells per treatment) in each
condition is indicated at the bottom of the figure. Cell lysates were immunoblotted for the indicated proteins. Results are representative of at least three inde-
pendent experiments.
(F) Left panels: THP-1 cells were treated with LPS (5 mg/ml) and PMA (50 nM) for 24 hr. For induction of apoptosis, cells were then treated with Act D (5 mM),
Daunorubicin (10 mM), Cisplatin (500 mM), or CHX (250 mM) for a further 12 hr before assessment of apoptosis by annexin V-FITC and propidium iodide (PI) staining
and flow cytometry. Cells and medium were harvested separately and cells were lysed as in (C). IL-33 and IL-1b amounts in cell lysates and medium were then
assessed by ELISA. Right panels: THP-1 cells were treated with LPS and PMA for 24 hr, as above. For induction of necrosis, cells were then treated for 1 hr with
hydrogen peroxide (H2O2; 20 mM), sodium azide (NaN2; 1 M), Streptolysin O (SLO; 10 mg/ml) or a high dose of Daunorubicin (100 mM) followed by assessment of
necrosis via PI uptake in conjunction with flow cytometry. Cells and medium were harvested separately and cells were lysed as in (C). IL-33 and IL-1b in the cell
lysates and media were assessed by ELISA. Results are representative of at least three independent experiments. Error bars represent the mean ± the SEM.Immunity 31, 84–98, July 17, 2009 ª2009 Elsevier Inc. 91
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(A) Upper panel: HEK293T cells were transfected with a ST2L receptor expression plasmid (200 ng per well of a 6-well plate) along with an NFkB luciferase
reporter plasmid (10 ng). Twenty-four hours later, the indicated concentrations of full-length or caspase-7-cleaved GST-IL-33 were added for a further 8 hr.92 Immunity 31, 84–98, July 17, 2009 ª2009 Elsevier Inc.
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Figure 5B) to ask whether these fragments could promote
ST2-dependent NF-kB activation. However, compared to either
full-length GST-IL-33 or the artificially truncated IL-33112-270,
when expressed independently neither fragment was found
to be capable of promoting ST2-dependent NF-kB activation
(Figure 5C).
Collectively, these data suggest that IL-33 is active as a full-
length molecule, or when artificially truncated after amino acid
111, and that caspase-mediated processing is not required for
the production of mature IL-33. These observations are reminis-
cent of the pattern of activity reported for IL-1a because this
cytokine displays biological activity both as a precursor and as
an N-terminally-truncated protein (Mosley et al., 1987). Thus,
the proposal that IL-33 is activated through proteolysis by cas-
pase-1 (Schmitz et al., 2005), similar to IL-1b and IL-18, appears
unfounded. Indeed, proteolytic processing of full-length IL-33 by
caspases considerably undermined the activity of this cytokine
(Figure 5A), possibly through destabilizing the protein and/or
by promoting the separation of IL-33 into fragments that are
incapable of promoting efficient ST2 receptor stimulation
(Figure 5C).
Pro-IL-33 Can Bind to the ST2 Receptor
Because the preceding experiments indicated that pro-IL-33
possessed ST2-dependent biological activity, this suggested
that full-length IL-33 was capable of interacting with the ST2
receptor. To confirm this, we performed in vitro pull-down
assays where we incubated sepharose-immobilized full-length
GST-IL-33, or caspase-cleaved GST-IL-33, with a soluble Fc-
ST2 fusion protein to determine whether both forms of IL-33
bound to the ST2 receptor. As Figure 5D shows, both forms of
GST-IL-33 specifically captured Fc-ST2 in the assay. We also
carried out the reciprocal experiment where we immobilized
Fc-ST2 on protein A/G agarose and assessed the binding of
soluble full-length GST-IL-33 or the caspase-cleaved form of
this protein (Figure 5E). Once again, we observed that both the
cleaved and the full-length forms of GST-IL-33 were able to
interact with the ST2 receptor.
We also carried out binding studies in ST2-transfected
HEK293 cells to compare binding of GST, GST-IL-33, andcaspase-7-cleaved GST-IL-33. Dose-dependent binding of
full-length GST-IL-33, but not GST, to ST2-transfected cells
was readily detected under these conditions. In agreement
with the in vitro pull-down experiments (Figures 5D and 5E),
the caspase-cleaved form of GST-IL-33 also bound to ST2-
transfected cells, but with reduced efficiency (Figures 5F and
5G). Because caspase-processed IL-33 was still capable of in-
teractingwith the ST2 receptor, this suggests that the loss of bio-
logical activity observed (Figure 5A) was unrelated to loss of
receptor binding per se but may be related to reduced binding
efficiency and/or other factors. Furthermore, although receptor
binding by the cleaved from of IL-33 was detected, it also
remains possible that the cleaved ligand may not activate the
ST2 receptor efficiently, and this may be responsible for the
reduced biological activity observed.
IL-33 Stability Is Modulated through Caspase-Mediated
Proteolysis
To explore the consequences of caspase-mediated cleavage of
IL-33 further, we asked whether caspase-mediated proteolysis
might destabilize this cytokine, possibly by opening themolecule
up to attack by serum proteases. To test this, we used the serum
protease a-chymotrypsin as a probe for IL-33 stability because
many cytokines are rapidly inactivated through degradation in
the peripheral circulation (Shechter et al., 2001). As Figure 6A
shows, whereas IL-33 was relatively resistant to proteolysis by
a-chymotrypsin, pretreatment of IL-33 with caspase-7 rendered
this cytokine much more susceptible to degradation by this
protease. Differential susceptibility of the caspase-cleaved
form of IL-33, versus the uncleaved form, to a-chymotrypsin-
mediated degradation was observed over a wide concentration
range (Figures 6A and 6B). Similar results were also observed in
response to proteinase K treatment (Figures 6C and 6D).
These data indicate that caspase-mediated proteolysis of
IL-33 provokes structural changes that render this cytokine
more susceptible to serum protease-mediated inactivation.
This suggests that rather than completely abolishing the biolog-
ical activity of IL-33 (by blocking ST2 receptor binding), cas-
pases may be involved in reducing the half-life of IL-33, by
increasing the sensitivity of this cytokine to attack by serum
proteases.Luciferase activity was assayed, in triplicate, in cell lysates and normalized against empty-vector-transfected cells. **p < 0.01 by Student’s t test. Lower panel: the
biological activity of His-tagged recombinant IL-33112-270 or caspase-7-cleaved IL-33112-270 was assessed as above. **p < 0.01 by Student’s t test. Results are
representative of at least three independent experiments. Error bars represent the mean ± the SEM.
(B) Schematic representation of IL-33 depicting the caspase cleavage site and the various His-tagged IL-33 deletion mutants generated for this study.
(C) Cells were transfected as in (A), followed by addition of the indicated molar amounts of GST-IL-33, the indicated deletion mutants of His-tagged IL-33, or
the control protein, PHAP. Cell lysates were assayed for luciferase activity 8 hr after addition of recombinant proteins. **p < 0.01 by Student’s t test. Results
are representative of at least three independent experiments. Error bars represent the mean ± the SEM.
(D) Upper panel: capture of soluble ST2-Fc after incubation with sepharose-immobilized GST, GST treated with caspase-7, GST-IL-33, or GST-IL-33 treated
with caspase-7, followed by probing for ST2. Lower panel: cleavage status of the IL-33 used for the pull-down assay was revealed by immunoblotting. Note
that ST2-Fc was pulled down with the full-length and the cleaved form of IL-33 (upper panel). Results are representative of at least two independent experiments.
(E) Protein A/G immobilized ST2-Fc was used to assess binding of GST, GST-IL-33 full-length, or cleaved GST-IL-33. Note that both the full-length and the
cleaved forms of IL-33 were captured by ST2, whereas the GST control was not. Results are representative of at least two independent experiments.
(F) Recombinant GST, GST-IL-33, or caspase-7-cleavedGST-IL-33 (all at 125 nM)were incubated for 1 hr with HEK293 cells stably expressing the ST2L receptor.
Cells were then surface immunostained with anti-GST or anti-IL-33 antibodies where appropriate. Binding of IL-33 was detected by flow-cytometry analysis.
Results are representative of at least three independent experiments.
(G) HEK293 cells expressing the ST2L receptor were incubated with the indicated concentrations of recombinant GST, GST-IL-33, or caspase-7-cleaved GST-
IL-33 for 1 hr followed by immunostaining with GST or IL-33 antibodies where appropriate. Binding of IL-33 was detected by flow-cytometry analysis. Results
are representative of at least three independent experiments.Immunity 31, 84–98, July 17, 2009 ª2009 Elsevier Inc. 93
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(A) Purified recombinant IL-33112-270 or caspase-cleaved IL-33112-270 was incubated for 2 hr at 37C in the presence of the indicated concentrations of a-chymo-
trypsin, followed by analysis by SDS-PAGE and Coomassie blue staining.
(B) Purified recombinant IL-33112-270 or caspase-cleaved IL-33112-270 was incubated for the indicated times at 37C with a-chymotrypsin (1 mg/ml) followed by
analysis by SDS-PAGE and Coomassie blue staining. Histograms represent the relative intensities of each IL-33 species normalized to the 0 hr time point. Gels
were quantitated with ImageJ software.
(C) Purified recombinant IL-33112-270 or caspase-cleaved IL-33112-270 was incubated for 2 hr at 37C in the presence of the indicated concentrations of Proteinase
K followed by analysis of cleavage reactions by SDS PAGE and Coomassie blue staining.
(D) Purified recombinant IL-33112-270 or caspase-cleaved IL-33112-270 was incubated at 37C with Proteinase K (25 ng/ml) for the indicated times followed by
analysis by SDS-PAGE and Coomassie blue staining. Histograms represent the relative intensities of each IL-33 species normalized to the 0 hr time point.
Gels were quantitated with ImageJ software. Results from (A)–(D) are representative of at least three independent experiments.TheCaspase-Cleaved Formof IL-33Exhibits Diminished
Activity In Vivo
To ask whether the caspase-cleaved form of IL-33 was also less
potent in vivo, we then compared the activity of both forms of
IL-33 in a mouse model. Mice treated with daily injections of
IL-33 (intraperitoneally [i.p.]) over a 6 day period exhibited
dramatic increases in splenic weight and cellularity (Figure 7A
and Figure S6A). Granulocyte numbers in the peritoneal space,
the peripheral blood, and the spleen were highly elevated
(Figures 7B and 7C and Figure S6B), with increases in eosinophil
numbers particularly evident (Figure 7C and Figure S6B). In addi-
tion, serum IL-4 and IL-5 concentrations were dramatically
elevated in response to IL-33, as previously reported (Figure 7D).94 Immunity 31, 84–98, July 17, 2009 ª2009 Elsevier Inc.Furthermore, IL-5 and IgA concentrations were also greatly
elevated in the lungs of IL-33-treatedmice (Figure 7D). Strikingly,
all of these responses were significantly attenuated in mice
treated with an identical regime of caspase-cleaved IL-33
(Figures 7A–7D and Figures S6A and S6B). Furthermore,
whereas restimulation of splenocytes and mesenteric lymph
node-derived lymphocytes from IL-33-treated mice resulted in
robust IL-5 production, these responses were also blunted in
mice treated with caspase-cleaved IL-33 (Figures 7E and 7F).
To rule out the possibility that residual caspase activity within
caspase-7-treated IL-33 preparations was responsible for the
reduced biological activity of this cytokine, we added the irre-
versible polycaspase inhibitor, zVAD-fmk, to both IL-33
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neutralization of caspase activity after treatment with zVAD-
fmk (Figure S7). Once again, caspase-cleaved IL-33 exhibited
greatly reduced potency in vivo compared to the uncleaved
protein (Figure S8), thereby ruling out the possibility that residual
caspase activity contributed to the effects seen.
Mutation of Asp178 Attenuates IL-33 Activity
In Vitro and In Vivo
Caspase-dependent proteolysis of IL-33could lead todecreased
biological activity by accelerating degradation by extracellular
proteases or by destabilizing a region of the protein critical
for proper receptor stimulation. To further explore the conse-
quences of proteolysis of IL-33 at Asp178, wewonderedwhether
mutation of this amino acid might affect the biological activity of
this cytokine. Therefore, we compared the activity of wild-type
IL-33, caspase-cleaved IL-33, and the IL-33D178A mutant
in vivo. As Figure S9 illustrates, wild-type IL-33 again displayed
potent biological activity in vivo, which was greatly attenuated
through caspase-mediated proteolysis, as before. Furthermore,
mutation of the caspase cleavage site at D178 also dramatically
reduced the biological potency of this cytokine, implying that
this region is critical for activity. With ST2-transfected HEK293
cells, the IL-33D178A mutant was also found to be inactive within
the NF-kB reporter assay (Figure S9H).
Collectively, these data provide strong support for the idea
that caspase-3- and caspase-7-mediated cleavage of IL-33
diminishes, rather than increases, the biological activity of this
cytokine through destabilizing a region within IL-33 that is impor-
tant for ST2 receptor stimulation.
DISCUSSION
Here we have shown that IL-33 is efficiently cleaved by
apoptosis-associated caspases (caspase-3 and -7) but not
inflammatory caspase-1, -4, or -5. Caspase-3 and -7 cleave IL-
33 at a motif (DGVD178 in human and DGVD175 in mouse) that
is fully conserved between the human and mouse forms of this
protein. Proteolysis of IL-33 was not required for ST2 receptor
binding or ST2 receptor-dependent NF-kB activation. Cas-
pase-dependent proteolysis of IL-33 attenuated ST2-dependent
NF-kB activation and increased susceptibility of IL-33 to degra-
dation by serum proteases. Furthermore, mutation of IL-33 at
Asp178 abolished the biological activity of this cytokine, sug-
gesting that proteolysis at this site alters the conformation of
a region within IL-33 that is critical for receptor signaling.
Because caspases are activated during apoptosis but not
necrosis, an interesting implication of our experiments is that
the half-life of IL-33 is reduced during apoptosis. Consistent
with this, IL-33 failed to undergo proteolytic processing in
necrotic cells (data not shown) but was readily cleaved during
apoptosis. Similar to IL-1a and IL-1b, IL-33 does not possess
a classical secretory sequence and is therefore unlikely to be
released from cells via the classical ER-Golgi secretory pathway.
Therefore, one possibility is that IL-33, similar to the nonclassical
cytokine HMGB1 (Scaffidi et al., 2002), is released as a conse-
quence of necrosis. Because caspases do not become activated
during necrotic cell death (Kroemer and Martin, 2005), IL-33 is
therefore likely to be released from necrotic cells as a full-lengthactive molecule. Caspase-dependent proteolysis of IL-33 during
apoptosis may therefore represent a means of reducing the
proinflammatory activity of this cytokine. Interestingly, it has
been demonstrated by several groups that apoptotic cells are
much less proinflammatory than necrotic cells and can even
exhibit anti-inflammatory effects that may dominate over
necrotic cell-derived factors (Voll et al., 1997; Patel et al.,
2007). Thus, the proteolysis of IL-33 during apoptosis may
contribute to the damping down of the potentially proinflamma-
tory effects of cell death. Furthermore, because apoptotic cells
are typically engulfed by phagocytes prior to loss of plasma-
membrane integrity, this further reduces the possibility of biolog-
ically active IL-33 being released from such cells. IL-33 may
therefore represent an endogenous ‘‘danger signal’’ or ‘‘alarmin’’
that is more potent when released in the context of pathological
cell death (necrosis) as opposed to apoptosis, which is more
usually encountered in physiological settings.
IL-33 is a nuclear protein that has been reported to possess
activity as a regulator of transcription (Carriere et al., 2007). IL-
1a also exhibits a nuclear expression pattern and is reported to
have intracellular activities (Maier et al., 1994). Furthermore,
pro-IL-1a is active as a full-length protein and is capable of
binding to the IL-1 receptor (Mosley et al., 1987). It is also sus-
pected that the major route of IL-1a release may be through
necrosis. Thus, IL-33 and IL-1a share several features in
common: both proteins are active as full-length molecules but
also undergo proteolytic processing under certain circum-
stances, and both are released during necrosis.
In conclusion, here we have shown that IL-33 is active as a full-
length cytokine, similar to IL-1a, and does not require proteolytic
maturation by inflammatory caspases for production of the
biologically active cytokine. However, IL-33 can be cleaved at
physiological concentrations of caspase-3 and -7, which greatly
attenuates the biological activity of this cytokine. Consistent with
this, IL-33 was processed at this cleavage motif within apoptotic
but not necrotic cells. Thus, contrary to the previous proposal
that caspase-1 activates IL-33 (Schmitz et al., 2005), caspase-
mediated proteolysis acts to suppress the proinflammatory
properties of this cytokine. Direct inactivation of a cytokine
represents a unique function for cell death-associated caspases
and suggests that caspases activated during apoptosis may
actively disable molecules with proinflammatory properties.
EXPERIMENTAL PROCEDURES
Reagents
Polyclonal antibodies were generated against hIL-33 by repeated immuniza-
tion of rabbits with the hIL-33 peptide 58CYFRRETTKRPSLKT72 (Sigma
Genosys, UK). Additional IL-33 antibodies were purchased from Alexis (UK)
and R&D systems (UK). Mouse IL-1b antibody was obtained from the National
Institute for Biological Standards and Control (UK). Antibodies specific to cas-
pase-3, caspase-7, RhoGDI, and XIAP were obtained from BD (UK). Anti-
human caspase-1 antibodieswere fromSanta Cruz (UK). Anti-IL-1b antibodies
were from R&D Systems (UK); anti-caspase-9 monoclonal antibodies were
from Oncogene Research Products (UK). Anti-co-chaperone p23 antibodies
were purchased from Affinity Bioreagents (UK). Anti-actin antibody was
purchased from ICN (UK). Anti-GR-1-FITC antibody was purchased from
ImmunoTools (Germany). The peptides z-YVAD-CHO, Ac-WEHD-AMC,
Ac-DEVD-AFC, and zVAD-FMK were all purchased from Bachem (UK).
Unless otherwise indicated, all other reagents were purchased from Sigma
(Ireland) Ltd.Immunity 31, 84–98, July 17, 2009 ª2009 Elsevier Inc. 95
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Bone marrow-derived DCs were generated from C57BL/6 mice as described
(Lavelle et al., 2001). WT, Casp1/, Casp3/, and Casp7/ MEFs were
derived from C57BL/6 mice. WT and Casp1/ MEFs were kindly provided
by Richard Flavell (Yale University, CT, USA), Casp3/ MEFs were kindly
provided by Afshin Samali (NUI Galway, Ireland), and Casp7/ MEFs were
kindly provided by Peter Vandenabeele (Ghent University, Belgium).
Expression and Purification of Recombinant IL-33 and Caspases
Recombinant GST-IL-33 and various His-tagged forms of IL-33 were ex-
pressed and purified as described in the Supplemental Experimental Proce-
dures. Recombinant polyhistidine-tagged caspase-1, -4, -5, -3, and -7 were
also expressed and purified as described in the Supplemental Experimental
Procedures.
Animals and In Vivo Treatment
C57BL/6 and Balb/c mice were obtained from Harlan (UK). Animal experi-
ments and maintenance were approved and regulated by the Trinity College
Dublin ethics committee and the Irish Department of Health.
Determination of Cytokine and IgA Levels
Cells were lysed in buffer containing 150 nM NaCl, 50 nM Tris (pH 8), 1%
NP-40, and 0.1% SDS. Cytokines in cell lysates or medium were detected
by ELISA with paired antibodies for IL-4, IL-5, IL-6 (BD PharMingen, UK),
IL-33, and IL-1b (R&D Systems, UK). IgA levels were measured as described
previously (Lavelle et al., 2001).
SUPPLEMENTAL DATA
Supplemental Data include nine figures and Supplemental Experimental
Procedures and can be found with this article online at http://www.
immunity.com/supplemental/S1074-7613(09)00269-6.
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